Generic drug "variations" guidance will extend ANDA "collapsibility," FDAer says.
This article was originally published in The Tan Sheet
Executive Summary
GENERIC DRUGS "VARIATIONS" GUIDANCE WILL EXTEND ANDA COLLAPSIBILITY to all dosage forms contained within a single abbreviated drug approval application, FDA Division of Labeling and Program Support Deputy Director Robert West reported at a Regulatory Affairs Professionals Society conference in Newark, N.J. April 3. Approximately 65% of all ANDAs submitted to the agency's Office of Generic Drugs are covered by current policy. The upcoming guidance, due by year end, will provide collapsibility criteria for the remaining 35%, West said.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: